Diabetes · San Francisco area, CA
Diabetes studies in San Francisco area, CA
37 recruiting studies have a site in the San Francisco area. This page includes nearby cities such as Oakland, Berkeley, San Mateo, Palo Alto.
37 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1Overnight stay mentioned
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
GentiBio, Inc
- Location
- Duarte, CA + 8 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersEarly Phase 1
Precision Dosing of Metformin in Youth With T2D
University of California, San Francisco
- Location
- Oakland, CA + 1 other US site
- Eligibility basics
- Ages 10–21
- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Beverly Hills, CA + 121 other US sites
- Eligibility basics
- Ages 55+
- Recruiting
SPYRAL GEMINI Pilot Study
Medtronic Vascular
- Location
- Stanford, CA + 11 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
Medtronic MiniMed, Inc.
- Location
- Chula Vista, CA + 9 other US sites
- Eligibility basics
- Ages 2–80
- RecruitingPhase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Boehringer Ingelheim
- Location
- Arcadia, CA + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie
- Location
- Bakersfield, CA + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Arcadia, CA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
- Location
- Concord, CA + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- San Diego, CA + 33 other US sites
- Eligibility basics
- Ages 1–25
- RecruitingPhase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
SAb Biotherapeutics, Inc.
- Location
- San Francisco, CA + 20 other US sites
- Eligibility basics
- Ages 5–40
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Irvine, CA + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Canoga Park, CA + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals
- Location
- Walnut Creek, CA + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Genentech, Inc.
- Location
- Beverly Hills, CA + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Canoga Park, CA + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Lake Forest, CA + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S
- Location
- Lomita, CA + 13 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Corxel Pharmaceuticals
- Location
- Cerritos, CA + 32 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
COUR Pharmaceutical Development Company, Inc.
- Location
- Newport Beach, CA + 44 other US sites
- Eligibility basics
- Ages 12–35
- RecruitingPhase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Lancaster, CA + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Vertex Pharmaceuticals Incorporated
- Location
- Duarte, CA + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation
- Location
- Los Angeles, CA + 9 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- Los Angeles, CA + 39 other US sites
- Eligibility basics
- Ages 10–17
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.